Lotte Bjerre Knudsen, a researcher closely associated with the development of GLP-1-based medicines, has said the food industry needs to pay attention to the impact of these drugs, according to the Financial Times. The newspaper published her remarks on Friday, 30 October 2026, under a headline quoting her view that the sector "has to listen."
The Financial Times report frames her comment around the growing influence of GLP-1 treatments, a class of medicines that has drawn widespread attention for its effects on appetite and weight. Knudsen is described by the publication as a pioneer in that field.
The report does not detail the specific changes she believes food companies should make, nor does it set out her full argument. The Financial Times summary presents her position as a direct message to an industry whose products are closely tied to eating habits.
Her remarks add to an ongoing conversation about how food manufacturers may need to adapt as GLP-1 medicines become more widely used. The Financial Times account places the food sector, rather than the pharmaceutical industry, at the center of that discussion.
What to watch next: whether food companies publicly respond to Knudsen's remarks, and whether the Financial Times follows up with a fuller account of her views.
